Table 1.
Haematological and clinical parameters at baseline and after 12 months of HU therapy of the study cohort
| Observation Total study population (n) = 128 | |||
|---|---|---|---|
| Parameters | Baseline (±SD) | POST HU (±SD) (10 mg/kg/day) | p value |
| Vaso-occlusive crisis (per year) £n1 = 111(86.7%) |
4.12 ± 0.9 | 0.23 ± 0.92 | <0.001 |
| Rate of blood transfusion (per year) £n2 = 46(35.93%) |
7.05 ± 1.07 | 0.52 ± 1.27 | <0.001 |
| Hb (g/dl)£ | 8.42 ± 1.14 | 9.78 ± 1.13 | <0.001 |
| MCV (fl) | 76.20 ± 8.20 | 90.78 ± 6.59 | <0.001 |
| MCH (pg) | 24.32 ± 2.69 | 26.24 ± 2.40 | <0.001 |
| TLC × 1000/mm3 | 12,283.48 ± 1307.34 | 8469.50 ± 1307.34 | <0.001 |
| Platelet count × 1000/mm3 | 242.48 ± 72.19 | 185.30 ± 52.89 | <0.001 |
| HbS (%) | 71.22 ± 5.01 | 68.39 ± 4.86 | <0.001 |
| HbF (%) | 18.06 ± 7.26 | 21.66 ± 6.77 | >0.05 |
| S.BILLIRUBIN(T) (mg/dl) | 2.19 ± 0.56 | 1.89 ± 0.54 | <0.001 |
| S.LDH (U/l) | 925.96 ± 135.54 | 742.02 ± 133.86 | <0.001 |
£n1, n2 are total no of cases presenting with repeated VOC and transfusion dependency respectively as per inclusion criteria